Simplified hierarchical linear models for the evaluation of surrogate endpoints
暂无分享,去创建一个
Geert Molenberghs | Russell D. Wolfinger | José Cortiñas Abrahantes | Theo Stijnen | Tomasz Burzykowski | Marc Buyse | Didier Renard | G. Molenberghs | M. Buyse | R. Wolfinger | T. Stijnen | F. Tibaldi | D. Renard | T. Burzykowski | J. Abrahantes | Fabian Tibaldi | Manesh Parmar | Max Parmar
[1] R J Carroll,et al. On meta-analytic assessment of surrogate outcomes. , 2000, Biostatistics.
[2] E. L. Lehmann,et al. Theory of point estimation , 1950 .
[3] G. Molenberghs,et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.
[4] Theo Stijnen,et al. Advanced methods in meta‐analysis: multivariate approach and meta‐regression , 2002, Statistics in medicine.
[5] Risto Lethonen. Multilevel Statistical Models (3rd ed.) , 2005 .
[6] Geert Molenberghs,et al. INVESTIGATING THE CRITERION VALIDITY OF PSYCHIATRIC SYMPTOM SCALES USING SURROGATE MARKER VALIDATION METHODOLOGY , 2002, Journal of biopharmaceutical statistics.
[7] Geert Molenberghs,et al. The validation of surrogate end points by using data from randomized clinical trials: a case‐study in advanced colorectal cancer , 2004 .
[8] C. Chuang-Stein,et al. Surrogate Endpoints in AIDS Drug Development: Current Status , 1998 .
[9] J. C. van Houwelingen,et al. Logistic Regression for Correlated Binary Data , 1994 .
[10] B. Graubard,et al. Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.
[11] Charles E. Heckler,et al. Applied Multivariate Statistical Analysis , 2005, Technometrics.
[12] T. Fleming,et al. Perspective: validating surrogate markers--are we being naive? , 1997, The Journal of infectious diseases.
[13] N. Breslow,et al. Approximate inference in generalized linear mixed models , 1993 .
[14] G. Molenberghs,et al. Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.
[15] G. Batist,et al. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Geert Molenberghs,et al. Statistical challenges in the evaluation of surrogate endpoints in randomized trials. , 2002, Controlled clinical trials.
[17] M J Daniels,et al. Meta-analysis for the evaluation of potential surrogate markers. , 1997, Statistics in medicine.
[18] H. Goldstein. Nonlinear multilevel models, with an application to discrete response data , 1991 .
[19] H. Goldstein. Multilevel Statistical Models , 2006 .
[20] Noreen Goldman,et al. An assessment of estimation procedures for multilevel models with binary responses , 1995 .
[21] P Flandre,et al. Estimating the proportion of treatment effect explained by a surrogate marker. , 1999, Statistics in Medicine.
[22] R. Wolfinger,et al. Generalized linear mixed models a pseudo-likelihood approach , 1993 .
[23] Harvey Goldstein,et al. Improved Approximations for Multilevel Models with Binary Responses , 1996 .
[24] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[25] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.
[26] M Buyse,et al. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] G. Molenberghs,et al. Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .